Cancer and Prognosis in Chronic Thromboembolic Pulmonary Hypertension
Author Information
Author(s): Fujii Hiroyuki, Taniguchi Yu, Tamura Yuichi, Sakamoto Miki, Yoneda Sachiyo, Yanaka Kenichi, Emoto Noriaki, Hirata Ken-ichi, Otake Hiromasa
Primary Institution: Kobe University Graduate School of Medicine
Hypothesis
What is the impact of comorbid cancer on the prognosis of patients with chronic thromboembolic pulmonary hypertension (CTEPH)?
Conclusion
Patients with CTEPH frequently have comorbid cancer, which may significantly affect their prognosis.
Supporting Evidence
- Patients with CTEPH and cancer had a lower 5-year survival rate compared to those without cancer.
- Among patients with cancer, those with active cancer had the worst survival rates.
- Multivariate analysis showed that cancer and hemodialysis were independently associated with poor survival.
Takeaway
This study found that many people with a lung problem called CTEPH also have cancer, which can make it harder for them to get better.
Methodology
The study analyzed data from 264 patients with CTEPH treated between January 2011 and December 2022, comparing those with and without cancer.
Potential Biases
Potential bias due to missing data and the retrospective nature of the study.
Limitations
The study is monocentric and retrospective, which may introduce bias and limit generalizability.
Participant Demographics
The average age of participants was 67 years, with 25% being male.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 0.08–0.60
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website